Literature DB >> 10955688

Livedoid vasculopathy in a patient with factor V mutation (Leiden).

T Biedermann1, M J Flaig, C A Sander.   

Abstract

BACKGROUND: Frequently, no underlying disease can be detected in patients with livedoid vasculopathy. For these forms, an unknown vaso-occlusive or thrombogenic process has been accused to play a role. Thus, a patient with livedoid vasculopathy was examined for different parameters which can be involved in coagulopathies.
METHODS: Laboratory studies for different autoantigen reactive immunoglobulins, cryoglobulins, and circulating immune complexes were carried out. Besides dermatopathologic examination, a biopsy specimen was analyzed by direct immunofluorescence for immunoglobulin (Ig) and complement deposits. Furthermore, hemostaseological function tests including activated protein C (APC) resistance were undertaken.
RESULTS: Positive only at very low titres were antinuclear antibodies and c-ANCA, all other parameters were within normal ranges or negative. Direct immunofluorescence revealed IgM, C3 and fibrogen deposits. Hemostaseological function tests demonstrated a pathologic activated protein c resistance and PCR analysis a heterozygous defect of the factor V (Leiden).
CONCLUSIONS: The diagnosis of livedoid vasculopathy associated with factor V mutation (Leiden) was made. Since the underlying cause for livedoid vasculopathy often remains unknown, we suggest that hemostaseological function tests including APC resistance and factor V gene mutation analysis should be carried out. Further studies have to follow in order to elucidate the role of mutant factor V in livedoid vasculopathy and in cutaneous ulcerations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955688     DOI: 10.1034/j.1600-0560.2000.027008410.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  4 in total

1.  Late failure of a split-thickness skin graft in the setting of homozygous factor V Leiden mutation: a case report and correlative animal model from the Wound Etiology and Healing (WE-HEAL) study.

Authors:  Victoria K Shanmugam; Sean McNish; Joanna Duncan; Brandy Root; Elena Tassi; Anton Wellstein; Bhaskar Kallakury; Christopher E Attinger
Journal:  Int Wound J       Date:  2013-09-13       Impact factor: 3.315

2.  Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.

Authors:  Mehmet Agirbasli; Mesut Eren; Fatih Eren; Sheila B Murphy; Zehra A Serdar; Dilek Seckin; Tuba Zara; M Cem Mat; Cuyan Demirkesen; Douglas E Vaughan
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

3.  Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity.

Authors:  Noha A Irani-Hakime; Farid Stephan; Raghid Kreidy; Isabelle Jureidini; Wassim Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2008-03-23       Impact factor: 2.300

4.  Painless Livedoid Vasculopathy in a Patient with G20210A Prothrombin Gene Mutation.

Authors:  Aibek E Mirrakhimov; Erwin Velasquez Kho; Alaa Ali
Journal:  Case Rep Med       Date:  2012-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.